Literature DB >> 30893189

Invasive Fungal Sinusitis: Risk Factors for Visual Acuity Outcomes and Mortality.

Kristin E Hirabayashi1, Oluwatobi O Idowu1, Evan Kalin-Hajdu2, Catherine E Oldenburg1,3, Frank L Brodie1, Robert C Kersten1, M Reza Vagefi1.   

Abstract

PURPOSE: Invasive fungal sinusitis is a rare but potentially lethal disease that primarily affects immunocompromised patients. The purpose of this study was to review an academic medical center's experience in the presentation, diagnosis, and treatment of invasive fungal sinusitis.
METHODS: A retrospective chart review was performed at a single institution over a 17-year period. Medical records, radiographic imaging, and operative reports were analyzed. Bivariate and multivariable analyses were performed to determine factors that affected visual acuity outcomes and mortality.
RESULTS: Fifty-five patients with histopathologically confirmed invasive fungal sinusitis were included. The average duration of follow up was 1.8 ± 2.6 years (range: 1 week to 10 years). The most common causes of immunosuppression were hematologic malignancy (45%), diabetes (31%), and organ transplantation (9%). At presentation, 35% of individuals were neutropenic (absolute neutrophil count < 500/μl). All patients received systemic antifungal treatment. A surgical intervention was performed on 50 patients (91%), and all but one had functional endoscopic sinus surgery. Nine (16%) patients underwent orbital exenteration. Multivariable analysis of visual acuity outcomes demonstrated that individuals infected with Zygomycota had 6-7 lines worse vision than those infected with Ascomycota (mean difference in logMAR 0.66, 95% confidence interval 0.27 to 1.06, p = 0.001). Patients who had functional endoscopic sinus surgery had 7-8 lines better visual acuity than those without functional endoscopic sinus surgery (mean difference in logMAR -0.76, 95% confidence interval -1.13 to -0.38, p < 0.001). The overall death rate due to infection was 24%. Bivariate models demonstrated no difference in mortality in patients receiving exenteration versus those who did not (p = 0.14). Multivariable analysis of mortality demonstrated that neutropenia increased mortality (adjusted odds ratio 10.05, 95% confidence interval 1.49 to 67.67, p = 0.02). Having a greater number of surgeries was associated with an increased rate of survival (adjusted odds ratio 0.39, 95% confidence interval 0.15 to 0.96, p = 0.04).
CONCLUSIONS: Invasive fungal sinusitis is an aggressive disease with significant mortality. Patients with neutropenia had a lower rate of survival, and infection with Zygomycota was associated with worse visual acuity outcomes. Those having functional endoscopic sinus surgery had better final visual acuity, and an increased number of surgeries was associated with a decreased chance of death. Exenteration yielded no observed survival benefit.Endoscopic sinus debridement portends better visual acuity outcomes in patients with invasive fungal sinusitis, whereas exenteration yields no difference in survival benefit.

Entities:  

Mesh:

Year:  2019        PMID: 30893189      PMCID: PMC9311235          DOI: 10.1097/IOP.0000000000001357

Source DB:  PubMed          Journal:  Ophthalmic Plast Reconstr Surg        ISSN: 0740-9303            Impact factor:   2.011


  22 in total

1.  Retrobulbar amphotericin B injections for treatment of invasive sino-orbital aspergillosis.

Authors:  Toshiko Wakabayashi; Hitoshi Oda; Naoki Kinoshita; Akiko Ogasawara; Yoshinori Fujishiro; Wakako Kawanabe
Journal:  Jpn J Ophthalmol       Date:  2007-08-03       Impact factor: 2.447

Review 2.  Invasive fungal sinusitis: treatment of the orbit.

Authors:  Evan Kalin-Hajdu; Kristin E Hirabayashi; M Reza Vagefi; Robert C Kersten
Journal:  Curr Opin Ophthalmol       Date:  2017-09       Impact factor: 3.761

3.  Retrobulbar Injection of Amphotericin B for Orbital Mucormycosis.

Authors:  Kristin E Hirabayashi; Evan Kalin-Hajdu; Frank L Brodie; Robert C Kersten; Matthew S Russell; M Reza Vagefi
Journal:  Ophthalmic Plast Reconstr Surg       Date:  2017 Jul/Aug       Impact factor: 1.746

4.  Invasive fungal disease of the sinus and orbit: a comparison between mucormycosis and Aspergillus.

Authors:  Danielle Trief; Stacey T Gray; Frederick A Jakobiec; Marlene L Durand; Aaron Fay; Suzanne K Freitag; N Grace Lee; Daniel R Lefebvre; Eric Holbrook; Benjamin Bleier; Peter Sadow; Alia Rashid; Nipun Chhabra; Michael K Yoon
Journal:  Br J Ophthalmol       Date:  2015-06-25       Impact factor: 4.638

5.  Intraorbital Irrigation of Amphotericin B in the Treatment of Rhino-Orbital Mucormycosis.

Authors:  Zachary P Joos; Bhupendra C K Patel
Journal:  Ophthalmic Plast Reconstr Surg       Date:  2017 Jan/Feb       Impact factor: 1.746

Review 6.  Immune reconstitution syndrome and fungal infections.

Authors:  Ashish O Gupta; Nina Singh
Journal:  Curr Opin Infect Dis       Date:  2011-12       Impact factor: 4.915

7.  Damage to Candida albicans hyphae and pseudohyphae by the myeloperoxidase system and oxidative products of neutrophil metabolism in vitro.

Authors:  R D Diamond; R A Clark; C C Haudenschild
Journal:  J Clin Invest       Date:  1980-11       Impact factor: 14.808

8.  Intraconal amphotericin B for the treatment of rhino-orbital mucormycosis.

Authors:  J D Luna; X S Ponssa; S D Rodríguez; N C Luna; C P Juárez
Journal:  Ophthalmic Surg Lasers       Date:  1996-08

9.  Acute Invasive Fungal Rhinosinusitis: A 15-Year Experience with 41 Patients.

Authors:  Sakeena J Payne; Ron Mitzner; Sudhir Kunchala; Lauren Roland; Johnathan D McGinn
Journal:  Otolaryngol Head Neck Surg       Date:  2016-02-16       Impact factor: 3.497

10.  Role of local amphotericin B therapy for sino-orbital fungal infections.

Authors:  S R Seiff; P H Choo; S R Carter
Journal:  Ophthalmic Plast Reconstr Surg       Date:  1999-01       Impact factor: 1.746

View more
  7 in total

Review 1.  The impact of mucormycosis (black fungus) on SARS-CoV-2-infected patients: at a glance.

Authors:  Md Rezaul Islam; Md Mominur Rahman; Md Tanjimul Ahasan; Nadia Sarkar; Shopnil Akash; Mahfuzul Islam; Fahadul Islam; Most Nazmin Aktar; Mohd Saeed; Md Harun-Or-Rashid; Md Kawsar Hosain; Md Saidur Rahaman; Sadia Afroz; Shabana Bibi; Md Habibur Rahman; Sherouk Hussein Sweilam
Journal:  Environ Sci Pollut Res Int       Date:  2022-08-19       Impact factor: 5.190

2.  Facial Nerve Palsy as a Common Presentation during the Epidemic of Coronavirus Disease Associated Rhinocerebral Mucormycosis.

Authors:  Y Mounika Reddy; Nitya Goddanti; Kiran Kumar; Aparna Suresh; Rajesh Muderla; T Shankar; Manish Gupta; K Sreenivas; Subramanyam Darbha
Journal:  Indian J Otolaryngol Head Neck Surg       Date:  2022-09-04

Review 3.  Rhino-orbital-cerebral mucormycosis as a complication of coronavirus disease 2019.

Authors:  Raid M Al-Ani
Journal:  World J Virol       Date:  2022-09-25

4.  Susceptibility of severe COVID-19 patients to rhino-orbital mucormycosis fungal infection in different clinical manifestations.

Authors:  Nurettin Bayram; Cemal Ozsaygılı; Hafize Sav; Yucel Tekin; Medine Gundogan; Emine Pangal; Ayse Cicek; İbrahim Özcan
Journal:  Jpn J Ophthalmol       Date:  2021-05-31       Impact factor: 2.447

5.  Acute Invasive Fungal Rhinosinusitis-Related Orbital Infection: A Single Medical Center Experience.

Authors:  Yu-Fang Huang; Kai-Li Liang; Chiao-Ying Liang; Po-Chin Yang; Jun-Peng Chen; Li-Chen Wei
Journal:  J Ophthalmol       Date:  2021-06-12       Impact factor: 1.909

6.  Acute Invasive Rhino-Orbital Mucormycosis in a Patient With COVID-19-Associated Acute Respiratory Distress Syndrome.

Authors:  Zesemayat K Mekonnen; Davin C Ashraf; Tyler Jankowski; Seanna R Grob; M Reza Vagefi; Robert C Kersten; Jeffry P Simko; Bryan J Winn
Journal:  Ophthalmic Plast Reconstr Surg       Date:  2021 Mar-Apr 01       Impact factor: 2.011

Review 7.  Coronavirus disease (COVID-19) complicated by rhino-orbital-cerebral mucormycosis presenting with neurovascular thrombosis: a case report and review of literature.

Authors:  Vahid Reza Ostovan; Shirin Rezapanah; Zahra Behzadi; Leila Hosseini; Reza Jahangiri; Mohammad Hossein Anbardar; Mahtab Rostami
Journal:  J Neurovirol       Date:  2021-08-03       Impact factor: 2.643

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.